BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company and inventors of the patent-pending molecular counter platform, which increases the resolution of cell-free DNA detection by over a thousandfold. BillionToOne's first product, UNITY, to be released in late spring 2019, will be the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF) and spinal muscular atrophy (SMA) through a single sample of the mother's blood. BillionToOne was co-founded by Oguzhan Atay, PhD, and David Tao, PhD.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/01/19 | $15,000,000 | Series A |
500 Startups Civilization Ventures Fifty Years HOF Capital Hummingbird Ventures  NeoTribe Ventures Y Combinator | undisclosed |
| 03/11/20 | $15,000,000 | Series A-1 |
500 Startups Civilization Ventures HOF Capital Hummingbird Ventures Libertus Capital NeoTribe Ventures Pacific 8 Ventures Y Combinator | undisclosed |
| 03/30/22 | $125,000,000 | Series C |
Adams Street Partners Baillie Gifford Civilization Ventures Fifty Years Hummingbird Ventures Libertus Capital NeoTribe Ventures Norwest Venture Partners Pacific 8 Ventures Time BioVentures | undisclosed |
| 12/15/22 | $48,500,000 | Venture |
Adams Street Partners Baillie Gifford Fifty Years Hummingbird Ventures Libertus Capital NeoTribe Ventures Norwest Venture Partners Time BioVentures | undisclosed |
